India, April 2 -- Bayer has reaffirmed its commitment to simplifying access to innovation in India and supporting early treatment for patients with retinal diseases in India. Bayer aims to expand the eligible patient pool for Eylea 2mg (intravitreal aflibercept injection) by lowering the upfront cost through a simpler access model. This initiative will enable more patients with Wet Age-Related Macular Degeneration (Wet AMD) and Diabetic Macular Edema (DME) to initiate treatment.

Wet AMD and DME are progressive retinal conditions that can lead to permanent vision loss if not treated in time. Both conditions require long-term management with intravitreal anti-VEGF therapy and regular monitoring by a retina specialist. For people with chron...